Fig. 1: Response rates. | Nature Communications

Fig. 1: Response rates.

From: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Fig. 1

Response after 3, 6, and 13 cycles or end of treatment. All patients were evaluable for response. Complete response is depicted in green, partial response in blue, and progressive disease in orange. No patients experienced stable disease. CR complete response, PR partial response, PD progressive disease. Source data are provided as a Source Data file.

Back to article page